MRI Versus PSA in Prostate Cancer Screening (MVP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02799303|
Recruitment Status : Unknown
Verified September 2019 by Dr. Robert Nam, Sunnybrook Health Sciences Centre.
Recruitment status was: Recruiting
First Posted : June 14, 2016
Last Update Posted : October 1, 2019
In this open randomized controlled trial, we seek to study whether prostate cancer screening using multiparametric prostate magnetic resonance imaging (mpMRI) improves the detection rate of clinically-significant prostate cancer (defined as Gleason score ≥7 on prostate biopsy) compared with prostate cancer screening using prostate-specific antigen (PSA).
The current paradigm of prostate cancer screening relies upon an initial PSA blood test, with subsequent investigations driven by the serum PSA level. This model has proven highly controversial due to the inability of PSA level to discern between indolent and aggressive forms of prostate cancer. As a result, numerous government-sponsored bodies have recommended against PSA screening. Evidence suggests that prostate cancer screening has led to an increased proportion of men being diagnosed with potentially curable prostate cancer. However, due to the inability of the PSA level to accurately distinguish patients with indolent and lethal forms of prostate cancer, it has led to a significant rate of over-diagnosis of indolent disease. Magnetic resonance imaging has been gaining an increasingly large role in the management of patients with clinically-localized prostate cancer including diagnosis in patients with abnormal PSA levels, monitoring of patients on active surveillance and staging prior to definitive interventions. MRI-based prostate cancer risk assessment has been shown to better distinguish between clinically-significant and insignificant tumors than PSA test. Therefore, a randomized controlled trial of MRI-based prostate cancer screening and PSA-based prostate cancer screening is warranted.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Device: Multi-parametric MRI Other: PSA testing||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1010 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Intervention not a drug/biologic.|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)|
|Actual Study Start Date :||June 2016|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
Experimental: Multi-parametric MRI
Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
Device: Multi-parametric MRI
Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
Active Comparator: PSA Only
Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.
Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician.
Other: PSA testing
Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
- Clinically-significant prostate cancer [ Time Frame: Within 3 years of randomization ]Gleason score greater than or equal to 7 on TRUS prostate biopsy
- Clinically-insignificant prostate cancer [ Time Frame: Within 3 years of randomizations ]Gleason score equal to 6 on TRUS prostate biopsy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02799303
|Contact: Robert Nam, MDfirstname.lastname@example.org|
|Sunnybrook Health Sciences Centre||Recruiting|
|Toronto, Ontario, Canada, M4N3M5|
|Contact: Mala Singh 4164806100 ext 7504 email@example.com|
|Principal Investigator:||Robert Nam, MD||Sunnybrook Health Sciences Centre|